Table 1.
Summary of the 7 reported patients with posttransplant cytopenias successfully treated with daratumumab
| Patient | Diagnosis | Conditioning | HSCT Source | Cytopenia onset after HSCT; daratumumab infusion timing | Treatment before daratumumab |
|---|---|---|---|---|---|
| Case report (PRCA)1 | MDS | Bu/Flu | MUD | First weeks; day 390 | High-dose steroids/rituximab/darbepoetin |
| Case report (AIHA)*2 | B ALL | Bu/Flu/Clo/alemtuzumab | MUD | Day 116; day 619 | MPN/rituximab/bortezomib/MMF/sirolimus/alemtuzumab/ibrutinib |
| XLT/WAS | Treo/Flu/Thio/alemtuzumab | MUD | Day 138; day 403 | Prednisolone/rituximab/plasmapheresis/MMF bortezomib | |
| DNA-ligase IV deficiency | Flu/Cy/alemtuzumab | MRD | Day 286; day 619 | Steroids/MMF/rituximab/ bortezomib/eculizumab | |
| Case report (Evans syndrome)3 | Severe aplastic anemia | Flu/Cy/alemtuzumab | MRD | 11 mo; ∼day 425 | Prednisolone/cyclosporine/IVIG/eltrombopag/rituximab/ romiplostim/bortezomib |
| Case report (AIHA)4 | B ALL | Bu/Flu/Clo/alemtuzumab | Mismatched unrelated donor | 1 mo; NA | MPN/rituximab/bortezomib/alemtuzumab/MMF/sirolimus/ibrutinib |
| Our patient | MDS | ATG/TLI | MUD | Day 152; ∼12 mo | MPN/vincristine/IVIG/rituximab/plasma exchange/splenectomy romiplostim/eltrombopag/danazol |
AIHA, autoimmune hemolytic anemia; ATG, anti-thymocyte globulin; B ALL, B-cell acute lymphocytic leukemia; Bu, busulfan; Clo, clofarabine; Cy, cyclophosphamide; Flu, fludarabine; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; MPN, methylprednisolone; MRD, matched related donor; MUD, matched unrelated donor; NA, not available; Thio, thiotepa; PRCA, pure red cell aplasia; TLI, total lymphoid irradiation; Treo, treosulfan; WAS, Wiskott-Aldrich syndrome; XLT, X-linked thrombocytopenia.
*
Three patients included in this case report.